Cargando…
The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19
Autores principales: | Nishikubo, Masashi, Shimomura, Yoshimitsu, Nagai, Yuya, Kondo, Tadakazu, Ishikawa, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665265/ http://dx.doi.org/10.1182/blood-2022-166433 |
Ejemplares similares
-
Meta-Analysis on Impact of Rituximab in Patients with Hematological Malignancies with Covid-19 Infection
por: Vegivinti, Charan Thej Reddy, et al.
Publicado: (2022) -
COVID-19: What do we know?
por: Marshall, Steve, et al.
Publicado: (2020) -
Hematologic Outcomes of COVID-19 Patients with and without G6PD Deficiency: A Comparative Study
por: Yassin, Mohamed A, et al.
Publicado: (2022) -
Cohort Profile: COVIDMENT: COVID-19 cohorts on mental health across six nations
por: Unnarsdóttir, Anna Bára, et al.
Publicado: (2021) -
Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan
por: Matsunaga, Nobuaki, et al.
Publicado: (2020)